CMA opens bipolar drug probe
The UK’s antitrust authority has launched an abuse of dominance investigation into Essential Pharma after the drugmaker threatened to withdraw a lithium-based bipolar disorder medication from the market.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.